Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
By Bhanvi Satija Oct 2 (Reuters) - Chinese biotech company Abogen said on Friday it has signed a licensing deal worth up to $7.8 billion with Novartis to develop messenger RNA-based therapy, underscoring the Swiss drugmaker's growing focus on an emerging class of treatments.